From the impact of Obamacare to cutting edge research, biotech buyouts to FDA decisions, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health-care, and their implications for long-term investors. In this week's edition, the team talks about the coming trend of penalizing unhealthy employees, the importance of drug branding, the avian flu outbreak, one stock investors need to watch, and more.
In the segment below, health care analyst Max Macaluso discusses two important things he's watching at biotech company Regeneron (NASDAQ:REGN).
The relevant video segment can be found between 7:54 and 9:22.
David Williamson and Max Macaluso, Ph.D. have no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
An immuno-oncology drug that's in the works could generate significant revenue growth someday.
This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
Shareholders aren't seeing too clearly after this double-dose of news concerning lead drug Eylea.
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Tiny start-up AnaptysBio helped spread fear that Dupixent's ongoing commercial launch might fizzle out.